Anti-Human MSTN Recombinant Antibody (H2L2) (CAT#: TAB-459MZ)

Figrue 1 shows binding of the H2L2-N54Q-C91S humanised anti-myostatin antibody variant to myostatin following treatment of the antibody with or without ammonium bicarbonate which can induce deamidation of the antibody.

Figure 2 shows binding of the H2L2-C91S humanised anti-myostatin antibody variant to myostatin following treatment of the antibody with or without ammonium bicarbonate which can induce deamidation of the antibody.

Figure 3 shows the H2L2-N54Q, H2L2-C91S, H2L2-N54Q-C91S humanised anti-myostatin antibody variants, H0L0, H2L2 and 10B3C inhibition of myostatin- induced activation of cell signalling, resulting in luciferase expression in A204 cells.

Figure 4 shows the binding of purified H2L2-N54Q, H2L2-C91S, H2L2- N54Q-C91S humanised anti-myostatin antibody variants, H2L2, HOLO and 10B3C (HCLC) to myostatin by ELISA.

Figure 5 shows 10B3, 10B3C, HOLO and H2L2 inhibition of myostatin- induced activation of cell signalling, resulting in luciferase expression in A204 cells.